Search

Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments
Dragging tomorrow into today: Meet Rachael Potter, Ph.D.
Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
Community Bulletin: BLA Accepted for Filing With Priority Review
Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues